Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy‐treated diffuse large B‐cell lymphoma
Open Access
- 25 January 2023
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 21 (2) , 200-207
Abstract
Diffuse large B‐cell lymphoma (DLBCL) is frequently treated with chemotherapy incorporating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), which induces remission in 80% to 95% of cases. However, not all dogs derive meaningful benefit from CHOP, and prognostic factors for dogs with DLBCL are poorly defined. Serum thymidine kinase 1 (TK1) activity, a marker of tumour cell proliferation, has shown promising initial results as a prognostic biomarker in dogs with multicentric lymphomas. The purpose of this study was to determine if baseline serum TK1 activity is associated with clinical outcome in dogs with CHOP‐treated DLBCL. Baseline serum TK1 activity was measured in banked sera from 98 dogs with CHOP‐treated DLBCL using a commercially available ELISA kit. Data on other potential prognostic factors were abstracted retrospectively from electronic medical records. Multivariable statistical methods were used to identify associations between TK1 and other potential prognostic factors with progression‐free survival (PFS) and attainment of complete remission. TK1 activity at baseline was not associated with PFS (p = .299) or attainment of complete remission (p = .910) following CHOP chemotherapy. Of the other prognostic factors analysed, only purebred (vs. mixed breed) status (HR 8.81, 95% CI 1.68–46.30, p = .010), attainment of complete (vs. partial) remission (HR 0.09, 95% CI 0.02–0.49, p = .006), and baseline serum C‐reactive protein concentration (HR 1.19, 95% CI 1.07–1.32, p = .001) were independently associated with PFS. Based on these findings, baseline serum TK1 activity does not appear to be a useful prognostic biomarker in dogs with CHOP‐treated DLBCL.Keywords
This publication has 27 references indexed in Scilit:
- C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patientsBritish Journal of Cancer, 2014
- Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoloneLeukemia & Lymphoma, 2013
- Evaluation of a 15‐weekCHOPprotocol for the treatment of canine multicentric lymphomaVeterinary and Comparative Oncology, 2012
- Prognostic Value of Platelet Count in Diffuse Large B-Cell LymphomaClinical Lymphoma Myeloma and Leukemia, 2012
- Classification of Canine Malignant Lymphomas According to the World Health Organization CriteriaVeterinary Pathology, 2010
- Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus documentVeterinary and Comparative Oncology, 2010
- Human C-Reactive Protein Binds Activating Fcγ Receptors and Protects Myeloma Tumor Cells from ApoptosisCancer Cell, 2007
- Serum Thymidine Kinase Activity in Dogs with Malignant Lymphoma: A Potent Marker for Prognosis and Monitoring the DiseaseJournal of Veterinary Internal Medicine, 2004
- Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2002
- Thymidine Kinases: The Enzymes and their Clinical UsefulnessCancer Biotherapy, 1993